LDH-AL6A inhibitors constitute a specialized chemical class designed to selectively target and modulate the function of Lactate Dehydrogenase A-like 6A (LDH-AL6A). LDH is a family of enzymes involved in cellular metabolism, particularly in the conversion of lactate to pyruvate. LDH-AL6A, as a specific variant within this family, likely exhibits unique structural and functional features that distinguish it from other LDH isoforms. The inhibitors developed for LDH-AL6A are meticulously crafted to interact with the specific molecular structure of this enzyme, aiming to disrupt its normal catalytic activities and potentially influencing cellular metabolic pathways.
The molecular architecture of LDH-AL6A inhibitors is precisely tailored to engage specific binding sites on the enzyme, inducing changes in its conformation and dynamics. This interaction holds the potential to impact the enzyme's ability to catalyze the conversion of lactate, thereby influencing the metabolic processes in which LDH-AL6A is involved. In laboratory research, these inhibitors serve as essential tools, allowing scientists to delve into the nuanced functions of LDH-AL6A in cellular metabolism. By manipulating the function of LDH-AL6A, researchers aim to unravel the intricate mechanisms governing metabolic pathways, contributing to a deeper understanding of cellular bioenergetics and potential implications for cellular function and development. The study of LDH-AL6A inhibitors stands at the forefront of advancing our comprehension of metabolic regulation within cells and the intricate interplay of enzymes in cellular processes.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Cisplatin | 15663-27-1 | sc-200896 sc-200896A | 100 mg 500 mg | $76.00 $216.00 | 101 | |
Cisplatin can form DNA adducts and disrupt DNA replication and transcription processes, potentially reducing gene expression. | ||||||
Actinomycin D | 50-76-0 | sc-200906 sc-200906A sc-200906B sc-200906C sc-200906D | 5 mg 25 mg 100 mg 1 g 10 g | $73.00 $238.00 $717.00 $2522.00 $21420.00 | 53 | |
By intercalating into DNA, it inhibits RNA polymerase and can decrease mRNA synthesis for many genes. | ||||||
Rifampicin | 13292-46-1 | sc-200910 sc-200910A sc-200910B sc-200910C | 1 g 5 g 100 g 250 g | $95.00 $322.00 $663.00 $1438.00 | 6 | |
It can inhibit bacterial RNA polymerase, and in eukaryotic cells, it might affect mitochondrial RNA polymerase. | ||||||
Chloroquine | 54-05-7 | sc-507304 | 250 mg | $68.00 | 2 | |
Known to intercalate into DNA and RNA, which may affect gene expression and protein synthesis. | ||||||
Camptothecin | 7689-03-4 | sc-200871 sc-200871A sc-200871B | 50 mg 250 mg 100 mg | $57.00 $182.00 $92.00 | 21 | |
As a topoisomerase I inhibitor, it prevents DNA unwinding, which is necessary for transcription. | ||||||
Mithramycin A | 18378-89-7 | sc-200909 | 1 mg | $54.00 | 6 | |
It binds to DNA and inhibits RNA synthesis by blocking RNA polymerase binding. | ||||||
α-Amanitin | 23109-05-9 | sc-202440 sc-202440A | 1 mg 5 mg | $260.00 $1029.00 | 26 | |
It is a potent inhibitor of RNA polymerase II in eukaryotic cells, leading to decreased mRNA production. | ||||||
Etoposide (VP-16) | 33419-42-0 | sc-3512B sc-3512 sc-3512A | 10 mg 100 mg 500 mg | $32.00 $170.00 $385.00 | 63 | |
This compound inhibits topoisomerase II, leading to DNA damage and potential suppression of transcription. | ||||||
Daunorubicin hydrochloride | 23541-50-6 | sc-200921 sc-200921A sc-200921B sc-200921C | 10 mg 50 mg 250 mg 1 g | $103.00 $429.00 $821.00 $1538.00 | 4 | |
By intercalating into DNA, it can inhibit the progression of RNA polymerase and affect gene transcription. | ||||||
Mitomycin C | 50-07-7 | sc-3514A sc-3514 sc-3514B | 2 mg 5 mg 10 mg | $65.00 $99.00 $140.00 | 85 | |
It crosslinks DNA, which can inhibit DNA synthesis and transcription. | ||||||